BCD-261
/ Biocad
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
July 25, 2025
ULTRAMARINE: A Randomized Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative Colitis
(clinicaltrials.gov)
- P2 | N=198 | Recruiting | Sponsor: Biocad
New P2 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
July 25, 2025
COMANDOR: Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's Disease
(clinicaltrials.gov)
- P2 | N=204 | Recruiting | Sponsor: Biocad
New P2 trial • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease
1 to 2
Of
2
Go to page
1